Advances in the treatment of diabetes-insulin analogues.

Z. Vajó, W. C. Duckworth

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Insulin analogues are molecules derived by modifying the structure of the human insulin molecule, resulting in altered physico-chemical, biological and pharmacodynamic properties. The pharmacokinetic characteristics of the previously available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. All currently available analogues have been shown to have a more physiological time-action profile with either a shorter onset and shorter duration of action (insulin lispro and insulin aspart) or a more constant effect lasting at least 24 hours (insulin glargine). These advantages in the time-action profiles have been shown to improve various surrogate parameters (e.g., postprandial blood glucose concentrations) in a number of randomized controlled trials. Insulin analogues also represent a unique tool to unravel structure-function relationships in insulin biochemistry and insulin action. Data on the currently available, currently tested and currently being developed analogs are reviewed.

Original languageEnglish
Pages (from-to)167-180
Number of pages14
JournalMinerva Endocrinologica
Volume27
Issue number3
Publication statusPublished - 2002

Fingerprint

Insulin
Insulin Aspart
Insulin Lispro
Biochemistry
Blood Glucose
Randomized Controlled Trials
Pharmacokinetics

Cite this

Advances in the treatment of diabetes-insulin analogues. / Vajó, Z.; Duckworth, W. C.

In: Minerva Endocrinologica, Vol. 27, No. 3, 2002, p. 167-180.

Research output: Contribution to journalArticle

Vajó, Z. ; Duckworth, W. C. / Advances in the treatment of diabetes-insulin analogues. In: Minerva Endocrinologica. 2002 ; Vol. 27, No. 3. pp. 167-180.
@article{71809481329c4f7cbcd2bb4eb726af9d,
title = "Advances in the treatment of diabetes-insulin analogues.",
abstract = "Insulin analogues are molecules derived by modifying the structure of the human insulin molecule, resulting in altered physico-chemical, biological and pharmacodynamic properties. The pharmacokinetic characteristics of the previously available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. All currently available analogues have been shown to have a more physiological time-action profile with either a shorter onset and shorter duration of action (insulin lispro and insulin aspart) or a more constant effect lasting at least 24 hours (insulin glargine). These advantages in the time-action profiles have been shown to improve various surrogate parameters (e.g., postprandial blood glucose concentrations) in a number of randomized controlled trials. Insulin analogues also represent a unique tool to unravel structure-function relationships in insulin biochemistry and insulin action. Data on the currently available, currently tested and currently being developed analogs are reviewed.",
author = "Z. Vaj{\'o} and Duckworth, {W. C.}",
year = "2002",
language = "English",
volume = "27",
pages = "167--180",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Advances in the treatment of diabetes-insulin analogues.

AU - Vajó, Z.

AU - Duckworth, W. C.

PY - 2002

Y1 - 2002

N2 - Insulin analogues are molecules derived by modifying the structure of the human insulin molecule, resulting in altered physico-chemical, biological and pharmacodynamic properties. The pharmacokinetic characteristics of the previously available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. All currently available analogues have been shown to have a more physiological time-action profile with either a shorter onset and shorter duration of action (insulin lispro and insulin aspart) or a more constant effect lasting at least 24 hours (insulin glargine). These advantages in the time-action profiles have been shown to improve various surrogate parameters (e.g., postprandial blood glucose concentrations) in a number of randomized controlled trials. Insulin analogues also represent a unique tool to unravel structure-function relationships in insulin biochemistry and insulin action. Data on the currently available, currently tested and currently being developed analogs are reviewed.

AB - Insulin analogues are molecules derived by modifying the structure of the human insulin molecule, resulting in altered physico-chemical, biological and pharmacodynamic properties. The pharmacokinetic characteristics of the previously available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. All currently available analogues have been shown to have a more physiological time-action profile with either a shorter onset and shorter duration of action (insulin lispro and insulin aspart) or a more constant effect lasting at least 24 hours (insulin glargine). These advantages in the time-action profiles have been shown to improve various surrogate parameters (e.g., postprandial blood glucose concentrations) in a number of randomized controlled trials. Insulin analogues also represent a unique tool to unravel structure-function relationships in insulin biochemistry and insulin action. Data on the currently available, currently tested and currently being developed analogs are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0036729775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036729775&partnerID=8YFLogxK

M3 - Article

C2 - 12091792

AN - SCOPUS:0036729775

VL - 27

SP - 167

EP - 180

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 3

ER -